ADPD 2025 Presentation
2025 ADPD:
ALTITUDE-AD: Use of a Validated Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Symptomatic Alzheimer’s Disease
File Type:
pdf
File Size:
932 KB
Categories:
2025
